Outlook Therapeutics (OTLK) Change in Accured Expenses: 2015-2024
Historic Change in Accured Expenses for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $491,728.
- Outlook Therapeutics' Change in Accured Expenses fell 15.90% to $511,157 in Q3 2020 from the same period last year, while for Sep 2020 it was $726,332, marking a year-over-year increase of 250.48%. This contributed to the annual value of $491,728 for FY2024, which is 169.10% up from last year.
- Outlook Therapeutics' Change in Accured Expenses amounted to $491,728 in FY2024, which was up 169.10% from -$711,661 recorded in FY2023.
- Over the past 5 years, Outlook Therapeutics' Change in Accured Expenses peaked at $726,332 during FY2020, and registered a low of -$5.3 million during FY2021.
- Moreover, its 3-year median value for Change in Accured Expenses was $156,141 (2022), whereas its average is -$21,264.
- Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 250.48% in 2020, then crashed by 829.58% in 2021.
- Outlook Therapeutics' Change in Accured Expenses (Yearly) stood at $726,332 in 2020, then tumbled by 829.58% to -$5.3 million in 2021, then spiked by 102.95% to $156,141 in 2022, then tumbled by 555.78% to -$711,661 in 2023, then soared by 169.10% to $491,728 in 2024.